bupropion

(redirected from Bupropion HCl)
Also found in: Dictionary.

bupropion

 [bu-pro´pe-on]
a compound structurally similar to amphetamine, used in the form of the hydrochloride salt as an antidepressant and as an aid in smoking cessation to reduce the symptoms of nicotine withdrawal; administered orally.

bupropion

(byo͞o-prō′pē-ŏn′)
n.
A drug, C13H18ClNO, used in its hydrochloride form for the treatment of depression and as an aid in smoking cessation. It is a weak inhibitor of norepinephrine and dopamine reuptake in the central nervous system.

bupropion

Zyban® Psychiatry An antidepressant Side effects Dry mouth, insomnia Contraindications Seizures, bulimia

bupropion

A drug used in the treatment of tobacco, drug and alcohol dependency. Bupropion reacts adversely with a wide range of other drugs and may induce seizures in sensitive persons. When used, a strict regime is necessary. A brand name is Zyban.

Bupropion

An antidepressant medication given to smokers for nicotine withdrawal symptoms. It is sold under the trade name Zyban.
References in periodicals archive ?
Annual sales of Wellbutrin SR 100mg and 200mg and the generic equivalent in that strength in the United States was USD115 million for the 12 months ending March 2010 according to IMS Health data.The addition of the 100mg and 200mg Bupropion HCl SR complements Actavis already approved and marketed Bupropion HCl SR 150mg.
Biopharmaceutical company Orexigen Therapeutics Inc (NasdaqGS:OREX) reported on Tuesday the launch of a distributorship agreement for Mysimba (naltrexone HCl / bupropion HCl prolonged release) in Italy.
Orexigen Therapeutics, Inc., a biopharmaceutical company helping to improve the health and lives of patients struggling with weight loss, announced that Health Canada has completed its screening phase and accepted for review a New Drug Submission for marketing approval of Contrave (naltrexone HCl and bupropion HCl).
India-based Dr Reddy's Laboratories has introduced Bupropion HCl extended-release tablets, USP (SR) in 100 mg, 150 mg and 200 mg, a therapeutic equivalent generic version of Wellbutrin SR (bupropion HCl) Sustained-Release Tablets, in the United States, it was reported yesterday.
In other generic product clearances by the regulatory agency, Actavis Group received approval to market bupropion HCl extended-release (SR) tablets 100 mg and 200 mg.
M2 PHARMA-September 5, 2016-Dr Reddy's Laboratories unveils Bupropion HCl Extended-Release Tablets, USP (SR) in the US market
Forfivo XL is the first 450 mg bupropion HCl tablet indicated for Major Depressive Disorder, approved by the FDA.
M2 EQUITYBITES-September 5, 2016-Dr Reddy's Laboratories unveils Bupropion HCl Extended-Release Tablets, USP (SR) in the US market
Biopharmaceutical company Orexigen Therapeutics (NasdaqGS:OREX) stated on Tuesday that it will commercialise Contrave (naltrexone HCl / bupropion HCl extended release) in Canada through a commercialisation and distributorship agreement with Valeant Canada, a subsidiary of Valeant Pharmaceuticals International or its affiliates, in the obesity medication market.
Orexigen Therapeutics Ireland, a wholly owned subsidiary of Orexigen Therapeutics, and Spain-based Laboratorios Farmaceuticos Rovi, SA have executed a commercialisation and distributorship agreement for Mysimba (naltrexone HCl / bupropion HCl prolonged release) in Spain, it was reported yesterday.
Orexigen Therapeutics, Inc and Takeda Pharmaceuticals U.S.A., Inc., a wholly-owned subsidiary of Takeda Pharmaceutical Company Limited, today announced they have agreed to terminate the Amended and Restated Collaboration Agreement for CONTRAVE (naltrexone HCl / bupropion HCl), the market leading national branded prescription treatment option for certain overweight and obese adults for chronic weight management.
Biopharmaceutical company Orexigen Therapeutics (NasdaqGS:OREX) said on Monday that its wholly owned subsidiary Orexigen Therapeutics Ireland Ltd has announced a commercialisation and distributorship agreement for Mysimba (naltrexone HCl / bupropion HCl prolonged release) in Spain in partnership with Laboratorios Farmaceuticos Rovi SA (ROVI).